News
European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback